IMGN
Income statement / Annual
Last year (2022), ImmunoGen, Inc.'s total revenue was $108.78 M,
an increase of 55.72% from the previous year.
In 2022, ImmunoGen, Inc.'s net income was -$222.93 M.
See ImmunoGen, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
06/30/2016 |
06/30/2015 |
06/30/2014 |
| Operating Revenue |
$108.78 M |
$69.86 M |
$132.30 M |
$82.27 M |
$53.82 M |
$115.45 M |
$48.63 M |
$60.00 M |
$85.54 M |
$59.90 M |
| Cost of Revenue |
$176,000.00
|
$0.00
|
$114.59 M
|
$114.52 M
|
$173.89 M
|
$139.74 M
|
$141.31 M
|
$146.92 M
|
$111.77 M
|
$106.96 M
|
| Gross Profit |
$108.61 M
|
$69.86 M
|
$17.71 M
|
-$32.25 M
|
-$120.07 M
|
-$24.29 M
|
-$92.68 M
|
-$86.91 M
|
-$26.23 M
|
-$47.06 M
|
| Gross Profit Ratio |
1
|
1
|
0.13
|
-0.39
|
-2.23
|
-0.21
|
-1.91
|
-1.45
|
-0.31
|
-0.79
|
| Research and Development Expenses |
$213.37 M
|
$151.12 M
|
$114.59 M
|
$114.52 M
|
$173.89 M
|
$139.74 M
|
$141.31 M
|
$146.92 M
|
$111.77 M
|
$106.96 M
|
| General & Administrative Expenses |
$0.00
|
$43.81 M
|
$38.60 M
|
$38.49 M
|
$36.72 M
|
$33.91 M
|
$38.53 M
|
$36.92 M
|
$28.23 M
|
$24.47 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$116.13 M
|
$43.81 M
|
$38.60 M
|
$38.49 M
|
$36.72 M
|
$33.91 M
|
$38.53 M
|
$36.92 M
|
$28.23 M
|
$24.47 M
|
| Other Expenses |
-$994,000.00
|
-$1.13 M
|
$1.21 M
|
$5.01 M
|
$3.33 M
|
$2.61 M
|
$0.00
|
$304,000.00
|
-$848,000.00
|
$167,000.00
|
| Operating Expenses |
$329.50 M
|
$194.93 M
|
$153.19 M
|
$153.01 M
|
$210.60 M
|
$173.65 M
|
$43.54 M
|
$183.83 M
|
$140.00 M
|
$131.43 M
|
| Cost And Expenses |
$329.68 M
|
$194.93 M
|
$153.19 M
|
$153.01 M
|
$210.60 M
|
$173.65 M
|
$184.85 M
|
$183.83 M
|
$140.00 M
|
$131.43 M
|
| Interest Income |
$0.00
|
$0.00
|
$729,000.00
|
$4.42 M
|
$0.00
|
$0.00
|
$20.51 M
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$4.17 M
|
$13.15 M
|
$23.20 M
|
$16.97 M
|
$10.73 M
|
$16.72 M
|
$0.00
|
$20.13 M
|
$5.44 M
|
$0.00
|
| Depreciation & Amortization |
$1.78 M
|
$2.02 M
|
$115.80 M
|
$26.45 M
|
$7.41 M
|
$5.96 M
|
$6.01 M
|
$5.33 M
|
$5.51 M
|
$4.60 M
|
| EBITDA |
-$220.10 M |
-$124.19 M |
-$19.68 M |
-$65.73 M |
-$153.45 M |
-$55.60 M |
-$125.20 M |
-$123.53 M |
-$55.30 M |
-$71.53 M |
| EBITDA Ratio |
-2.02
|
-1.78
|
-0.15
|
-0.8
|
-2.85
|
-0.48
|
-2.57
|
-2.06
|
-0.65
|
-1.19
|
| Operating Income Ratio |
-2.03
|
-1.79
|
-1.02
|
-1.12
|
-2.98
|
-0.51
|
-2.7
|
-2.06
|
-0.64
|
-1.19
|
| Total Other Income/Expenses Net |
$3.35 M
|
-$1.08 M
|
-$21.99 M
|
-$11.96 M
|
-$8.36 M
|
-$37.03 M
|
-$25.52 M
|
-$19.83 M
|
-$6.28 M
|
$167,000.00
|
| Income Before Tax |
-$221.71 M
|
-$139.30 M
|
-$44.37 M
|
-$104.13 M
|
-$167.87 M
|
-$96.01 M
|
-$156.73 M
|
-$143.66 M
|
-$60.74 M
|
-$71.36 M
|
| Income Before Tax Ratio |
-2.04
|
-1.99
|
-0.34
|
-1.27
|
-3.12
|
-0.83
|
-3.22
|
-2.39
|
-0.71
|
-1.19
|
| Income Tax Expense |
$1.22 M
|
$0.00
|
$22.31 M
|
$17.96 M
|
$7.39 M
|
$37.03 M
|
$0.00
|
$19.83 M
|
$6.28 M
|
-$167,000.00
|
| Net Income |
-$222.93 M
|
-$139.30 M
|
-$66.68 M
|
-$122.09 M
|
-$167.87 M
|
-$96.01 M
|
-$156.73 M
|
-$143.66 M
|
-$60.74 M
|
-$71.36 M
|
| Net Income Ratio |
-2.05
|
-1.99
|
-0.5
|
-1.48
|
-3.12
|
-0.83
|
-3.22
|
-2.39
|
-0.71
|
-1.19
|
| EPS |
-0.87895012833605 |
-1.0814079273528 |
-0.38 |
-0.82 |
-1.2 |
-0.98 |
-1.8 |
-1.65 |
-0.71 |
-0.83 |
| EPS Diluted |
-0.87895012833605 |
-1.0814079273528 |
-0.38 |
-0.82 |
-1.2 |
-0.98 |
-1.8 |
-1.65 |
-0.71 |
-0.83 |
| Weighted Average Shares Out |
$253.63 M
|
$206.15 M
|
$176.15 M
|
$148.31 M
|
$139.95 M
|
$98.07 M
|
$87.08 M
|
$86.98 M
|
$86.04 M
|
$85.48 M
|
| Weighted Average Shares Out Diluted |
$253.63 M
|
$206.15 M
|
$176.15 M
|
$148.31 M
|
$139.95 M
|
$98.07 M
|
$87.08 M
|
$86.98 M
|
$86.04 M
|
$85.48 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
